NEW YORK--(BUSINESS WIRE)--Alliqua, Inc. (OTCBB: ALQA) (FWB: HL1) (“Alliqua” or the “Company”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office to enhance its transdermal delivery technology. The filing was based on positive test results with respect to specific chemical agents that improved the delivery of active ingredients when used in conjunction with the Company’s hydrogel drug delivery platform. The patent application is directed to specific formulations that management believes will enhance the performance of its platform.
